ADARx Pharmaceuticals priced its $446.3 million Nasdaq IPO, underscoring renewed appetite for RNA-focused biotechs. The company sold more than 26 million shares at $17—at the top end of its range—after also securing additional support from AbbVie via a private investment, according to the coverage. The proceeds are positioned to fund development across ADARx’s RNA interference pipeline, including late-stage hereditary angioedema work, while the separate AbbVie partnership reinforces the monetization strategy that has been increasingly common for platform biotechs. The listing also signals investors’ continued interest in RNA mechanisms beyond the liver, despite historical delivery and potency hurdles. For the biotech sector, the immediate impact is liquidity and momentum in the IPO window—potentially drawing attention to other RNA and precision-medicine stories with similar platform narratives.